GSK and CureVac formed a partnership during the Covid-19 pandemic to develop mRNA vaccines against the novel coronavirus and other infectious diseases. GSK will now have full control of developing and manufacturing the avian influenza vaccine and two other vaccine candidates, for which they will pay up to €1.05 billion based on milestones. CureVac’s technology platform optimizes mRNA constructs to induce immune responses, with second-generation candidates showing improved stability and translation in cells. The restructuring will also see layoffs at CureVac to focus on innovation and R&D. GSK aims to streamline vaccine development and focus on oncology programs with the revised agreement.
Source link
GSK Pays CureVac €400M to Pick Up Clinical-Stage mRNA Vaccines for Infectious Diseases
